Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Prothena Corporation plc Ordinary Shares · PHARMACEUTICAL PREPARATIONS · Now $10.18
+12% in 7d after detection
Post-detection moves
1h
—
1d
+3.1%
3d
+8.4%
7d
+12%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS